000905419 001__ 905419
000905419 005__ 20220131120330.0
000905419 037__ $$aFZJ-2022-00660
000905419 041__ $$aEnglish
000905419 1001_ $$0P:(DE-Juel1)177012$$aHahn, Lisa$$b0$$eFirst author$$ufzj
000905419 1112_ $$aDGPPN Kongress$$cBerlin$$d2021-11-24 - 2021-11-27$$gDGPPN$$wGermany
000905419 245__ $$aResting-state alterations in behavioral variant frontotemporal dementia are related to the distribution of monoamine and GABA neurotransmitter systems
000905419 260__ $$c2021
000905419 3367_ $$033$$2EndNote$$aConference Paper
000905419 3367_ $$2DataCite$$aOther
000905419 3367_ $$2BibTeX$$aINPROCEEDINGS
000905419 3367_ $$2DRIVER$$aconferenceObject
000905419 3367_ $$2ORCID$$aLECTURE_SPEECH
000905419 3367_ $$0PUB:(DE-HGF)6$$2PUB:(DE-HGF)$$aConference Presentation$$bconf$$mconf$$s1642508814_6598$$xAfter Call
000905419 520__ $$aIntroduction: Aside to changes in personality and behavior, behavioral variant frontotemporal dementia (bvFTD) is characterized by progressive structural and functional alterations in frontal and temporal regions. Only little is known about the underlying mechanisms leading to the anatomical constraints of the pathophysiology. Here, we evaluated if these alterations are linked to the distribution of specific neurotransmitter systems.Methods: Maps of fractional amplitude of low frequency fluctuations (fALFF) were derived as a measure of local activity from resting state functional magnetic resonance imaging for 52 bvFTD patients and 22 healthy controls (HC). We tested if alterations in the fALFF signal of bvFTD patients co-localize with the known non-pathological distribution of specific neurotransmitter systems and their coding mRNA gene expression. Furthermore, we evaluated if the strength of this co-localization is associated with respective symptom severity.Results: Compared to HC, patients displayed significantly reduced fractional amplitude of low frequency fluctuations in fronto-temporal and fronto-parietal regions. These alterations significantly co-localized with the distribution of serotonin (5-HT1b, 5-HT2a), dopamine (D2), and gamma-aminobutyric acid type A receptors, the noradrenaline transporter, and their encoding mRNA gene expression. The strength of the co-localization with D2 and noradrenaline transporter was associated with cognitive symptoms of bvFTD. Conclusion: Local brain functional activity reductions in bvFTD follow the distribution of specific neurotransmitter systems supporting the notion of the preferential vulnerability of specific neurotransmitter systems. These findings provide novel insight into neuropathophysiological mechanisms underlying functional alterations in bvFTD.
000905419 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000905419 7001_ $$0P:(DE-Juel1)131678$$aEickhoff, Simon$$b1$$ufzj
000905419 7001_ $$0P:(DE-HGF)0$$aConsortium, German FTLD$$b2
000905419 7001_ $$0P:(DE-HGF)0$$aOtto, Markus$$b3
000905419 7001_ $$0P:(DE-Juel1)177727$$aDukart, Jürgen$$b4$$eCorresponding author$$ufzj
000905419 7001_ $$0P:(DE-HGF)0$$aSchroeter, Matthias$$b5$$eCorresponding author
000905419 909CO $$ooai:juser.fz-juelich.de:905419$$pVDB
000905419 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177012$$aForschungszentrum Jülich$$b0$$kFZJ
000905419 9101_ $$0I:(DE-HGF)0$$6P:(DE-Juel1)177012$$a Institute of Systems Neuroscience, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany$$b0
000905419 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131678$$aForschungszentrum Jülich$$b1$$kFZJ
000905419 9101_ $$0I:(DE-HGF)0$$6P:(DE-Juel1)131678$$a Institute of Systems Neuroscience, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany$$b1
000905419 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Neurology, Ulm University, Ulm, Baden-Württemberg, Germany$$b3
000905419 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177727$$aForschungszentrum Jülich$$b4$$kFZJ
000905419 9101_ $$0I:(DE-HGF)0$$6P:(DE-Juel1)177727$$a Institute of Systems Neuroscience, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany$$b4
000905419 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany$$b5
000905419 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Clinic for Cognitive Neurology, University Hospital Leipzig, Germany$$b5
000905419 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000905419 9141_ $$y2021
000905419 920__ $$lyes
000905419 9201_ $$0I:(DE-Juel1)INM-7-20090406$$kINM-7$$lGehirn & Verhalten$$x0
000905419 980__ $$aconf
000905419 980__ $$aVDB
000905419 980__ $$aI:(DE-Juel1)INM-7-20090406
000905419 980__ $$aUNRESTRICTED